3647 results for «686»
3647 results
TAVI: new approach
20 May 2026 – From EuroPCR 2026
This session introduces new frontiers in transcatheter aortic valve implantation (TAVI), including artificial intelligence-enabled systems and minimalist, radiation-free approaches guided by echocardiography. It covers complex procedural techniques such as axillary access under TEE guidance, precision snaring, and managing challenging anatomies, emphasizing advancements in safety and efficacy...
Registries and trials in mitral TEER
20 May 2026 – From EuroPCR 2026
This comprehensive session reviews registries and clinical trials in mitral transcatheter edge-to-edge repair (TEER). It includes discussions on novel TEER systems, international consensus on PASCAL implants, anatomical predictors of procedural success, and long-term outcomes including ventricular and atrial remodeling after intervention, as well as emerging therapies...
AI in imaging & the cathlab - opportunities in procedural planning & guidance
20 May 2026 – From EuroPCR 2026
This session explores the role of artificial intelligence in imaging and the cathlab, emphasizing computer vision applications distinct from language models. It discusses AI's integration into procedural planning and guidance, balancing algorithmic support with physician judgement to enhance interventional cardiology workflows.
Imaging the calcified lesions: what you need to see
20 May 2026 – From EuroPCR 2026
This session emphasizes critical imaging aspects necessary for assessing calcified coronary lesions. It addresses lesion-specific Agatston scoring, OCT-guided PCI optimization, coronary CT planning, histopathological insights, and predictors of stent underexpansion after calcium modification.
A randomised trial comparing imaging-guided PCI with Orsiro vs Xience
18 May 2021
Previous clinical trials suggested that ultra-thin strut biodegradable polymer sirolimus-eluting stent (BP-SES) may be associated with lower target lesion failure (TLF) when compared to durable polymer everolimus-eluting stents (DP-EES). However, the possible underlying mechanisms remain unclear. Therefore, the all-comers CASTLE study was designed to assess the...
Authors :
RIVER: Rivaroxaban for valvular heart disease and atrial fibrillation
05 Sep 2023
Alex Sticchi provides his take on the results of the RIVER trial, which were presented by Pedro Gabriel Barros E Silva during the ESC 2023 congress in Amsterdam.
Rivaroxaban versus Warfarin in Patients with Bioprosthetic Valves According to Valvular Heart Disease Etiology, and Thrombotic and Bleeding Risks: Insights from...

Author
BIOFLOW DAPT - Biodegradable-polymer or durable-polymer stents in patients at high bleeding risk: A randomized, open-label clinical trial
26 Aug 2023
Nicola Ryan reports on the BIOFLOW DAPT trial results presented during the ESC 2023 Congress in Amsterdam by Marco Valgimigli and published in Circulation.
BIOFLOW-DAPT is an open-label randomised trial comparing the safety and efficacy of a biodegradable-polymer sirolimus-eluting stent with a durable-polymer zotarolimus-eluting stent in high-bleeding risk patients...

Author